Drug-Induced Autoimmune-Like Hepatitis (Q37843783)

24 August 2017

1 reference

title

Drug-induced autoimmune-like hepatitis (English)

1 reference

24 August 2017

Drug-Induced Autoimmune-Like Hepatitis (English)

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1611-4

24 November 2024

Albert J. Czaja

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21327704

24 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21327704

24 November 2024

publication date

16 February 2011

1 reference

full work available at URL

24 August 2017

https://link.springer.com/content/pdf/10.1007/s10620-011-1611-4.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1611-4

https://link.springer.com/article/10.1007/s10620-011-1611-4/fulltext.html

24 November 2024

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1611-4

http://link.springer.com/content/pdf/10.1007/s10620-011-1611-4

24 November 2024

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1611-4

Digestive Diseases and Sciences

24 November 2024

published in

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

958-976

1 reference

Diagnosis and management of autoimmune hepatitis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Autoimmune hepatitis. Part B: diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Extrahepatic immunologic features of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Histological findings in chronic hepatitis C with autoimmune features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Autoimmune hepatitis with incidental histologic features of bile duct injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Drug-induced autoimmune hepatitis: clinical characteristics and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Simplified criteria for the diagnosis of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Performance parameters of the diagnostic scoring systems for autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Immune-mediated drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Drug-induced liver injury: summary of a single topic clinical research conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Histological patterns in drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Pathology of immune-mediated liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Incidence of drug-induced liver injury in medical inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Risk factors for idiosyncratic drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Incidence of drug-induced hepatic injuries: a French population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Classification, etiology, and considerations of outcome in acute liver failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Drug-induced hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Antibiotic therapy: a major cause of drug-induced jaundice in southwest England

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Acute and clinically relevant drug-induced liver injury: a population based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Important elements for the diagnosis of drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Drug-induced active chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Drug-induced chronic liver disease, with emphasis on chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Meloxicam as a cause of drug-induced autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Methylphenidate-induced autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Liver Disease Caused by Propylthiouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Autoimmune hepatitis revealed by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Drug-induced liver injury associated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Rosuvastatin-associated hepatitis with autoimmune features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Serious liver disease induced by infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Adalimumab-induced autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Hepatotoxicity due to hydroxycut: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Fulminant exacerbation of autoimmune hepatitis after the use of ma huang

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Autoimmune hepatitis associated with the use of black cohosh: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Delineating liver events in trichloroethylene-induced autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Halothane hepatitis: a model of immune mediated drug hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Identification of the dihydrolipoamide acetyltransferase subunit of the human pyruvate dehydrogenase complex as an autoantigen in halothane hepatitis. Molecular mimicry of trifluoroacetyl-lysine by lipoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Study of immune reactivity of minocycline-induced chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Immune phenotype of chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Minocycline-induced autoimmune syndromes: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

21 January 2018

Minocycline hepatitis.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Minocycline and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Nitrofurantoin: another cause of drug-induced chronic active hepatitis? A report of a patient with HLA-B8 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

The natural history of histologically proved drug induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Morphologic Alterations in Patients with Alpha-Methyldopa-induced Liver Damage after Short- and Long-term Exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Epidemiology and individual susceptibility to adverse drug reactions affecting the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

The influence of age and sex on the clearance of cytochrome P450 3A substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Causality assessment of drug-induced hepatotoxicity: promises and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Idiosyncratic drug reactions: current understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Hepatic injury caused by mianserin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

The rational use of potentially hepatotoxic medications in patients with underlying liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Pharmacogenetics of drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Familial occurrence of hypersensitivity to phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Criteria of drug-induced liver disorders. Report of an international consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Metabonomics and its role in drug development and disease diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Assessment of hepatotoxic liabilities by transcript profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Autoimmune hepatitis. Part A: pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Idiosyncratic drug reactions: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Elucidating mechanisms of drug-induced toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Drug-induced immunotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Genetic association studies in drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Tolerance, danger, and the extended family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Current concepts of mechanisms in drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Idiosyncratic drug hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Physiology and pathophysiology of autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

NKT cells: facts, functions and fallacies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Acute liver failure: mechanisms of immune-mediated liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Fas polymorphisms influence susceptibility to autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

The role of Ifng in alterations in liver gene expression in a mouse model of fulminant autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Current and future treatments of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Rapidity of treatment response and outcome in type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

The quality of published adverse drug event reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Chronic active hepatitis and giant multinucleated hepatocytes in adults treated with clometacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Methyldopa-induced immune hemolytic anemia and chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Minocycline-induced hepatitis with autoimmune features and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Prognosis of histological cirrhosis in type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Autoimmune hepatitis in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Is autoimmune chronic active hepatitis a HCV-related disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1611-4

Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities

21 January 2018

1 reference

12 December 2020

Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C

1 reference

12 December 2020

Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease

1 reference

12 December 2020

Autoimmune hepatitis triggered by administration of an herbal medicine.

1 reference

12 December 2020

Performance parameters of the conventional serological markers for autoimmune hepatitis

1 reference

12 December 2020

Lymphocyte reactivity to ex-vivo drug antigens in drug-induced hepatitis

1 reference

12 December 2020

Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9

1 reference

12 December 2020

Pemoline-induced autoimmune hepatitis

1 reference

12 December 2020

Drug-induced liver disease

1 reference

12 December 2020

Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis

1 reference

12 December 2020

Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug

1 reference

12 December 2020

Validation of scoring system for diagnosis of autoimmune hepatitis

1 reference

12 December 2020

Anti-cytochrome P450 autoantibodies in drug-induced disease.

1 reference

12 December 2020

A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis

1 reference

12 December 2020

Host- and disease-specific factors affecting steatosis in chronic hepatitis C

1 reference

12 December 2020

Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury

1 reference

12 December 2020

Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis

1 reference

12 December 2020

Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor α agents.

1 reference

12 December 2020

Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis

1 reference

12 December 2020

Nitrofurantoin-induced chronic active hepatitis.

1 reference

12 December 2020

Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting

1 reference

12 December 2020

Papaverine-induced chronic liver disease

1 reference

12 December 2020

Evidence for prostaglandin-producing suppressor cells in drug-induced liver injury and implications in the diagnosis of drug sensitization

1 reference

12 December 2020

Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge

1 reference

12 December 2020

Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis

1 reference

12 December 2020

Liver Injury with Features Mimicking Autoimmune Hepatitis following the Use of Black Cohosh

1 reference

12 December 2020

Are patients with elevated liver tests at increased risk of drug-induced liver injury?

1 reference

12 December 2020

The lymphocyte transformation test--a debated method for the evaluation of drug allergic hepatic injury

1 reference

12 December 2020

[Chronic active hepatitis associated with antinuclear antibodies induced by fenofibrate]

1 reference

12 December 2020

Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis

1 reference

12 December 2020

Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: A nationwide study

1 reference

12 December 2020

Drug-induced chronic liver disease

1 reference

12 December 2020

Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies

1 reference

12 December 2020

Duration of immunosuppressive therapy in autoimmune hepatitis

1 reference

12 December 2020

Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis

1 reference

12 December 2020

A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis

1 reference

12 December 2020

Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis

1 reference

12 December 2020

Hospital admissions due to adverse drug reactions. A report from the Boston Collaborative Drug Surveillance Program.

1 reference

12 December 2020

Changing clinical patterns in acute liver failure

1 reference

12 December 2020

Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly

1 reference

12 December 2020

Propylthiouracil hepatotoxicity mimicking autoimmune chronic active hepatitis in a girl

1 reference

12 December 2020

Clinicopathological features of acute-onset autoimmune hepatitis

1 reference

12 December 2020

Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim

1 reference

12 December 2020

Features and consequences of untreated type 1 autoimmune hepatitis

1 reference

12 December 2020

Drug-induced hepatitis with autoimmune features during minocycline therapy.

1 reference

12 December 2020

Consequences of treatment withdrawal in type 1 autoimmune hepatitis

1 reference

12 December 2020

Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis.

1 reference

12 December 2020

Methyldopa Hepatitis. A report of six cases and review of the literature

1 reference

12 December 2020

Increased presence of common systemic lupus erythematosus (SLE) anti-DNA idiotypes (16/6 Id, 32/15 Id) is induced by procainamide

1 reference

12 December 2020

Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis

1 reference

12 December 2020

Hy's law: predicting serious hepatotoxicity

1 reference

12 December 2020

Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: Correlation of serum transaminase and gamma globulin levels with histologic features

1 reference

12 December 2020

Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis

1 reference

12 December 2020

Critical reflection on the collection and evaluation of adverse drug reaction data

1 reference

12 December 2020

Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre

1 reference

12 December 2020

Chronic active hepatitis caused by benzarone

1 reference

12 December 2020

Long-term hepatic memory for hypersensitivity to nitrofurantoin

1 reference

12 December 2020

Acute hepatitis associated with the use of a Chinese herbal product, ma-huang.

1 reference

12 December 2020

Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations

1 reference

12 December 2020

Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse

1 reference

12 December 2020

Diclofenac-associated hepatotoxicity

1 reference

12 December 2020

Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic

1 reference

12 December 2020

Interferon-induced chronic active hepatitis?

1 reference

12 December 2020

Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity

1 reference

12 December 2020

Causality assessment versus guilt-by-association in drug hepatotoxicity

1 reference

12 December 2020

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States

1 reference

12 December 2020

Chronic active hepatitis and cirrhosis induced by wild germander. 3 cases

1 reference

12 December 2020

Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period

1 reference

12 December 2020

Comparison of two clinical scales for causality assessment in hepatotoxicity

1 reference

12 December 2020

The validity and importance of subtypes in autoimmune hepatitis: a point of view

1 reference

12 December 2020

Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients

1 reference

12 December 2020

Isoniazid-associated hepatitis in 114 patients

1 reference

12 December 2020

Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin

1 reference

12 December 2020

Long-term follow-up of patients with mild to moderate drug-induced liver injury

1 reference

12 December 2020

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

12 December 2020

Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience

1 reference

12 December 2020

Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice

1 reference

12 December 2020

[Hepatitis caused by clometacin (Dupéran). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?].

1 reference

12 December 2020

Safety issues in the management of autoimmune hepatitis

1 reference

12 December 2020

Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions

1 reference

12 December 2020

The nature and prognostic implications of autoimmune hepatitis with an acute presentation

1 reference

12 December 2020

Drug-induced liver disease

1 reference

12 December 2020

Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission

1 reference

12 December 2020

Modifications of the lymphocyte transformation test in a case of drug-induced cholestatic hepatitis

1 reference

12 December 2020

Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis

1 reference

12 December 2020

Animal models of autoimmune hepatitis

1 reference

12 December 2020

Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis

1 reference

12 December 2020

Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period. Incidence and prognosis.

1 reference

12 December 2020

Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.

1 reference

12 December 2020

Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis

1 reference

12 December 2020

Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1611-4

24 November 2024

Molecular Pharmacology

280

M Bourdi

1992

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1611-4

24 November 2024

Molecular Pharmacology

100

1287

M Bourdi

1994

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1611-4

24 November 2024

Molecular Pharmacology

125

326

S Lecoeur

1996

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1611-4

24 November 2024

Diagnostic immunology

163

177

RM Victorino

1985

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1611-4

International journal of clinical pharmacology, therapy, and toxicology

24 November 2024

221

S48

J Venulet

1985

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1611-4

24 November 2024

239

303

GL Davis

1982

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1611-4

24 November 2024

Identifiers

1 reference

24 August 2017

1 reference